Display options
Share it on

Front Behav Neurosci. 2014 Jun 11;8:215. doi: 10.3389/fnbeh.2014.00215. eCollection 2014.

A new approach to assess gambling-like behavior in laboratory rats: using intracranial self-stimulation as a positive reinforcer.

Frontiers in behavioral neuroscience

Stephanie E Tedford, Nathan A Holtz, Amanda L Persons, T Celeste Napier

Affiliations

  1. Department of Pharmacology, Center for Compulsive Behavior and Addiction, Rush University Medical Center Chicago, IL, USA ; Department of Pharmacology, Rush University Medical Center Chicago, IL, USA.
  2. Department of Pharmacology, Center for Compulsive Behavior and Addiction, Rush University Medical Center Chicago, IL, USA ; Department of Pharmacology, Rush University Medical Center Chicago, IL, USA ; Department of Psychiatry, Rush University Medical Center Chicago, IL, USA.

PMID: 24966822 PMCID: PMC4052818 DOI: 10.3389/fnbeh.2014.00215

Abstract

Pathological gambling is one manifestation of impulse control disorders. The biological underpinnings of these disorders remain elusive and treatment is far from ideal. Animal models of impulse control disorders are a critical research tool for understanding this condition and for medication development. Modeling such complex behaviors is daunting, but by its deconstruction, scientists have recapitulated in animals critical aspects of gambling. One aspect of gambling is cost/benefit decision-making wherein one weighs the anticipated costs and expected benefits of a course of action. Risk/reward, delay-based and effort-based decision-making all represent cost/benefit choices. These features are studied in humans and have been translated to animal protocols to measure decision-making processes. Traditionally, the positive reinforcer used in animal studies is food. Here, we describe how intracranial self-stimulation can be used for cost/benefit decision-making tasks and overview our recent studies showing how pharmacological therapies alter these behaviors in laboratory rats. We propose that these models may have value in screening new compounds for the ability to promote and prevent aspects of gambling behavior.

Keywords: cost/benefit decision-making; discounting; effort-based decision-making; gambling; intracranial self-stimulation

References

  1. Exp Clin Psychopharmacol. 2009 Oct;17(5):283-90 - PubMed
  2. J Exp Psychol Anim Behav Process. 1998 Oct;24(4):439-52 - PubMed
  3. J Abnorm Psychol. 2012 Feb;121(1):151-9 - PubMed
  4. Ann N Y Acad Sci. 1992 Jun 28;654:192-8 - PubMed
  5. J Abnorm Child Psychol. 1994 Jun;22(3):281-302 - PubMed
  6. Neuropsychopharmacology. 2012 May;37(6):1397-408 - PubMed
  7. Psychol Rev. 1969 May;76(3):264-81 - PubMed
  8. Neuropsychopharmacology. 2010 Oct;35(11):2155-64 - PubMed
  9. Neuropsychopharmacology. 2009 Sep;34(10):2329-43 - PubMed
  10. Science. 2010 Jul 30;329(5991):532 - PubMed
  11. Prog Neuropsychopharmacol. 1981;5(5-6):467-74 - PubMed
  12. Annu Rev Neurosci. 1996;19:319-40 - PubMed
  13. Ann Neurol. 2011 Jun;69(6):986-96 - PubMed
  14. Behav Brain Res. 2014 Jun 1;266:19-28 - PubMed
  15. PLoS Biol. 2004 Dec;2(12):e402 - PubMed
  16. Psychol Med. 2011 Dec;41(12):2625-35 - PubMed
  17. Brain Res. 1980 Mar 3;185(1):1-15 - PubMed
  18. Psychiatry Res. 2014 Mar 30;215(3):675-82 - PubMed
  19. Neuropsychol Rev. 2009 Mar;19(1):102-14 - PubMed
  20. Annu Rev Psychol. 1989;40:191-225 - PubMed
  21. Behav Processes. 2010 Jan;83(1):23-30 - PubMed
  22. J Neuropsychol. 2013 Sep;7(2):306-25 - PubMed
  23. Nervenarzt. 2006 Aug;77(8):958-60 - PubMed
  24. Int J Neurosci. 1981;15(4):217-22 - PubMed
  25. Pharmacol Ther. 2012 Jun;134(3):287-97 - PubMed
  26. Behav Processes. 2004 Jan 30;65(1):35-42 - PubMed
  27. Exp Clin Psychopharmacol. 2010 Jun;18(3):267-76 - PubMed
  28. Neuropsychopharmacology. 2014 Jun;39(7):1558-67 - PubMed
  29. Behav Processes. 2003 Oct 31;64(3):345-354 - PubMed
  30. Psychopharmacology (Berl). 2011 Jan;213(1):11-8 - PubMed
  31. Arch Gen Psychiatry. 2012 Feb;69(2):177-86 - PubMed
  32. Behav Brain Res. 2014 May 1;264:230-9 - PubMed
  33. J Neurosci. 2011 Nov 16;31(46):16597-602 - PubMed
  34. J Neurosci Methods. 1997 Jun 6;74(1):17-26 - PubMed
  35. Behav Processes. 2003 Oct 31;64(3):355-367 - PubMed
  36. PLoS One. 2008 Jun 25;3(6):e2479 - PubMed
  37. Psychon Bull Rev. 2009 Dec;16(6):1071-5 - PubMed
  38. Behav Pharmacol. 2011 Aug;22(4):300-11 - PubMed
  39. PLoS One. 2009 Aug 12;4(8):e6598 - PubMed
  40. Pharmacol Biochem Behav. 1986 Jul;25(1):63-9 - PubMed
  41. J Comp Physiol Psychol. 1954 Dec;47(6):419-27 - PubMed
  42. Neurodegener Dis. 2013;11(2):72-8 - PubMed
  43. Drug Alcohol Depend. 2009 Nov 1;105(1-2):89-96 - PubMed
  44. J Atten Disord. 2016 Nov;20(11):968-978 - PubMed
  45. Mov Disord. 2011 Sep;26(11):2004-10 - PubMed
  46. Pharmacol Biochem Behav. 2014 Mar;118:1-9 - PubMed
  47. J Neurosci Methods. 2011 Jun 15;198(2):260-9 - PubMed
  48. Pharmacol Ther. 2012 Dec;136(3):343-53 - PubMed
  49. Cogn Affect Behav Neurosci. 2011 Mar;11(1):97-112 - PubMed
  50. J Comp Physiol Psychol. 1962 Oct;55:671-8 - PubMed
  51. J Comp Neurol. 2005 Dec 5;493(1):115-21 - PubMed
  52. J Neurophysiol. 2009 Jan;101(1):437-47 - PubMed
  53. Neuropsychopharmacology. 2009 Feb;34(3):681-97 - PubMed
  54. J Exp Anal Behav. 1991 Mar;55(2):233-44 - PubMed
  55. J Appl Behav Anal. 2003 Winter;36(4):449-58 - PubMed
  56. Arch Neurol. 2010 May;67(5):589-95 - PubMed
  57. Exp Clin Psychopharmacol. 2000 May;8(2):155-62 - PubMed
  58. Psychopharmacology (Berl). 2008 Feb;196(2):221-32 - PubMed

Publication Types

Grant support